Elan shareholders mull the unravelling of a business
How the Irish biotech firm got to this point and how the EGM may play out
Elan puts itself on market as prospects for restructuring plan fade
Review of proxies suggests stalemate after four-month battle for control of company
Royalty gets injunction in challenge to Takeover Panel on Elan bid
Court move means bid will not lapse pending full hearing even if shareholders back certain resolutions
Failure of Royalty Pharma bid likely to hit Elan share price, say analysts
Fate of $6.7bn offer will be decided by shareholders at extraordinary general meeting on Monday
Elan urges shareholders to “protect the value of their investment”
Pharmaceutical firm continues to urge shareholders to reject Royalty Pharma offer on grounds it is “grossly inadequate”
Elan shareholders to vote on new acquisitions
If all transactions are approved, Elan will have spent $3.3bn on M&A, share buybacks and bond redemptions
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Election 2024
Full general election coverage including analysis and results for all 43 constituencies
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices